CVS Caremark survey shows 91% of employers worry about rising prescription drug prices
Reuters2026/08/12 15:13- CVS Health-backed CVS Caremark survey flagged employer focus on rising drug prices, specialty access, biosimilars, GLP-1 spending.
- 91% of employers reported concern over high medication prices for employees; 88% viewed PBMs as well positioned to cut costs.
- Only 49% encouraged biosimilar substitution; 40% considered it; 12% educated employees on potential savings.
- CVS Caremark reported over USD 3.3 billion in gross Humira-related savings since April 2024 from biosimilar formulary strategy.
- 77% cited GLP-1 coverage costs as a concern; 80% limited weight-loss GLP-1 coverage or considered limits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why hasn’t the rise in US Treasury yields boosted the US dollar exchange rate?
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
Crypto prices
More
